INSILICO (03696) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 2.69%, trading at HK$62.95, with a turnover of HK$75.9963 million. On May 7, the company announced the official release of its latest intelligent laboratory operating system, LabClaw. As the pharmaceutical industry's first laboratory automation system designed with a lightweight intelligent agent (Agent-Guard) architecture, LabClaw is specifically tailored for INSILICO's LifeStar2 fully automated laboratory. It aims to drive a paradigm shift in intelligent laboratories from "executing commands" to "autonomous coordination." The system establishes a new tripartite experimental model of "AI thinking, machine execution, and human supervision," deeply integrating INSILICO's proprietary AI target discovery platform PandaOmics, automated laboratory hardware matrix, laboratory information management system (LIMS), and multi-dimensional data analysis pipelines. Through five collaborative AI agents and 28 professional skill modules, LabClaw successfully builds an end-to-end intelligent closed loop for both dry and wet lab processes, spanning from disease target discovery and compound screening to automated experiment execution and data analysis with report generation.